Lilly’s weight-loss pill shows better blood sugar control in late-stage trials
Eli Lilly’s experimental oral weight-loss drug, orforglipron, demonstrated superior blood sugar control in diabetic patients across two late-stage trials. The drug, designed to mimic the GLP-1 hormone, showed significant A1C reductions and weight loss, potentially setting a new standard of care for type 2 diabetes.
Consensus: Bisphosphonates for Aromatase Inhibitor Bone Loss
The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture risk linked to aromatase inhibitor use in hormone-sensitive breast cancer. Medscape Medical News
Increase in Physicians Walking Away From Clinical Practice
The proportion of physicians leaving clinical practice has increased since 2013. Medscape Medical News
Hormones, Menopause, and Weight Loss: What to Tell Patients
During menopause, women often deal with biological, physical, and emotional issues — to help them lose weight, clinicians need to be supportive and personalize treatment. Medscape Medical News
A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity
礼来口服GLP-1药物在后期临床试验中有效降低血糖水平
Lilly”s oral GLP-1 drug helps reduce blood sugar levels in late-stage trials (www.reuters.com) 18:51
In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails to Catch On
COLUMBUS, Miss. — April Hines has battled with her weight since she was a teenager. But in the past couple of years, she’s fallen from 600 pounds to 385, and her blood pressure and blood sugar levels are down, too. “I’m not as fatigued as I used to be, and I’ve been able to go […]
GLP-1 drugs may delay alcohol’s effects in the bloodstream
There’s mounting evidence that popular drugs prescribed for diabetes management and weight loss—better known by trade names like Ozempic and Wegovy—could be effective in reducing alcohol use.
GLP-1 craze fuels rise of protein snacks with new Protein Pop-Tarts, Doritos coming – Axios
GLP-1 craze fuels rise of protein snacks with new Protein Pop-Tarts, Doritos coming Axios Pop-Tarts Is Releasing a First-Of-Its-Kind Product—and We Want Every Flavor Allrecipes Food firms scramble to meet the high-protein craze BBC From Doritos to Pop-Tarts, Big Food’s $67 billion obsession is protein-packed everything: ‘It’s going to keep coming’ Fortune Pop-Tarts brings back #1 fan-requested flavor, launches […]
Infected necrotizing pancreatitis: clinical features, microbial patterns, and outcomes in a Saudi tertiary center
Infected necrotizing pancreatitis (INP) is a severe complication of acute pancreatitis (AP) associated with high morbidity and mortality, yet regional data remain limited. We retrospectively reviewed 119 patients admitted with AP to the King Abdulaziz University Hospital, Jeddah, Saudi Arabia, between 2017 and 2025 to characterize risk factors, microbiological profiles, and management strategies. Of these […]